Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: smh who wrote (3685)	5/5/2001 12:42:34 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

smh, Just recovering from a biotech OD - visited a bunch of companies over two days together with some other biofreaks. Thanks everyone for taking care of the thread while I was gone. On ASCO, one comment I heard was that this was overall a relatively slow news year. Glivec will obviously (and rightly so) be front and center. I hold a number of cancer stocks, none in large quantities. The three that I think might get most hype out of ASCO are IMCL, IMGN and TELK. CELG and MOGN are also presenting and might also pop if they break any news. Now back to recuperation. <g> Peter

To: smh who wrote (3685)	5/14/2001 3:31:17 PM
From: Biomaven	Respond to of 52153

SMH, << So in this negative overall environment, ASCO ended up being viewed as a selling op. (My recollection is that's what happened last year as well). What this means is that moderate news is not going to drive the biotechs higher right now. >> Peter, hopefully this year will be much different. Nope. <g> Peter